SML1945
IMB-808
≥98% (HPLC)
别名:
2,3-Dihydro-N-methyl-N-[2-oxo-2-[(2,3,4-trifluorophenyl)amino]ethyl]-1,4-benzodioxin-6-carboxamide, N-Methyl-N-(2-oxo-2-((2,3,4-trifluorophenyl)amino)ethyl)-3,4-dihydro-2H-benzo[b][1,4] dioxin-7-carboxamide
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
Assay:
≥98% (HPLC)
Form:
powder
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
SMILES string
FC1=C(NC(CN(C)C(C2=CC(OCCO3)=C3C=C2)=O)=O)C=CC(F)=C1F
InChI
1S/C18H15F3N2O4/c1-23(9-15(24)22-12-4-3-11(19)16(20)17(12)21)18(25)10-2-5-13-14(8-10)27-7-6-26-13/h2-5,8H,6-7,9H2,1H3,(H,22,24)
InChI key
XITZPIXICJOKTF-UHFFFAOYSA-N
Biochem/physiol Actions
IMB-808 is a potent Liver X receptor α and β (LXRα/β) partial dual agonist that promotes expression of genes related to reverse cholesterol transport (including ABCA1 and ABCG1), and associated with cholesterol metabolism pathway in multiple cell lines (including ApoE). Also IMB-808 promotes cholesterol efflux from macrophages and reduced the accumulated lipids of foam cells.
potent Liver X receptor α and β (LXRα/β) partial dual agonist
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Ni Li et al.
Molecular pharmacology, 91(4), 264-276 (2017-01-15)
Activation of liver X receptor (LXR) is associated with cholesterol metabolism and anti-inflammatory processes, which makes it beneficial to antiatherosclerosis therapy. Nevertheless, existing agonists that target LXR, for example TO901317, are related to unwanted side effects. In the present study
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| SML1945-5MG | 04061833058732 |
| SML1945-25MG | 04061833058725 |